OBJECTIVE： To investigate the effects of fluvastatin combined with aspirin on the related indicators of patients with diabetic lower extremity arteriosclerosis occlusive desease （LEAOD）. METHODS： 80 patients with diabetic LEAOD were randomly divided into control group （40 cases） and observation group （40 cases）. Based on convertional treatment， control group was given Rosuvastatin calcium tablet 5 mg+Aspirin enteric-coated tablet 100 mg every evening； observation group was given Fluvastatin sodium capsule 40 mg+Aspirin enteric-coated tablet 100 mg. They were treated for 3 months. Fibrinogen， plasma D-dimer， blood viscosity， cholesterol （TC）， triglyceride （TG）， glycosylated hemoglobin （HbAlc）， low-density lipoprotein cholesterol （LDL-C）， high-density lipoprotein cholesterol （HDL-C）， carotid intima-media thickness， compliance situation of TC， TG， HbAlc， LDL-C and HDL-C， cases of carotid intima thickening， plaque formation， stenosis and occlusion before and after treatment were observed， and the incidence of adverse reactions was recorded. RESULTS： After treatment， fibrinogen， plasma D-dimer， blood viscosity， TC， TG， HbAlc， LDL-C and carotid intima-media thickness in 2 groups were significantly lower than before treatment， and observation group was significantly lower than control group； HDL-C in 2 groups was significantly higher than before， and observation group was significantly higher than control group， with statistical significance （P＜0.05）. Compliance rates of TC， TG， LDL-C and HDL-C in observation group were significantly higher than control group， proportion of carotid intima thickening and carotid plaque formation were significantly less than control group， with statistical significance （P＜0.05）， there were no significant differences in the compliance rate of HbA1c， proportion of carotid stenosis and occlusion and the incidence of adverse reactions in 2 groups（P＞0.05）. CONCLUSIONS： Fluvastatin combined with aspirin can significantly improve the patients’ blood viscosity， blood lipid， vascular endothelial function in the treatment of diabetic LEAOD， it can reduce the thrombotic disease risk， and does not increase the incidence of adverse reactions.